A Phase Ib Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SY-008 After Multiple Ascending Doses in Patients With Type 2 Diabetes Mellitus
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Maximum postprandial (breakfast, lunch, dinner) blood glucose added value.
研究概览
简要总结
This is a phase Ib placebo-controlled study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of SY-008 after Multiple Ascending Doses in patients with Type 2 Diabetes Mellitus (T2DM).
详细描述
This is a multicenter, randomized, double-blind, placebo-controlled, dose-increasing, multiple oral administration clinical trial. The planned dose increasing level was 6, 12 and 18 mg daily dose (3 administration groups).
After the completion of the test and safety evaluation of the initial dose 6mg daily dose group, the main researchers of the team leader and the sponsor jointly determine whether to enter the 12mg daily dose study.
After the completion of the test and safety evaluation of the 12 mg daily dose group, the main researchers of the team leader and the sponsor jointly determine whether to enter the 18 mg daily dose study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •body weight of male ≥ 50kg, female ≥ 45kg, and body mass index (BMI) between 18.0 and 35.0 kg / m2 (including the threshold value) at screening;
- •Have T2DM prior to entering the trial based on the disease diagnostic criteria (WHO, 1999), and currently being treated with diet and exercise only for at last 12 weeks , or no systemic treatment of diabetes (the cumulative use of antidiabetic drugs in the past 3 months has lasted no more than 2 weeks and no antidiabetic drugs has been used in the past month);
- •7% ≤ HbA1c ≤ 9.5% at screening;
- •7 mmol/L≤FPG ≤ 13.3 mmol/L at baseline;
- •During the study period and within 60 days after the end of the study, the subjects has no fertility or sperm / egg donation plan and will voluntarily take effective physical contraceptive measures;
- •Have given written informed consent to participate in this study, are well motivated, capable, and willing to communicate with the investigator and complete all the requirements according to the protocol.
排除标准
- •Those who are known to be allergic to the test drug (including the auxiliary materials of the test drug) or its analogues, or who are allergic to two or more drugs, food and pollen, or who have taken SGLT1 or SGLT2 inhibitors in the past year;
- •It was diagnosed as type 1 diabetes, or gestational diabetes, or other special type diabetes;
- •There is enough evidence to show that there is proliferative retinopathy of active diabetes;
- •History of severe hypoglycemia (such as consciousness disorder and coma caused by hypoglycemia), or history of severe unconsciousness hypoglycemia;
- •Organ transplantation history, or other acquired, congenital immune system diseases, or peripheral vascular diseases with clinical significance;
- •Have significant hyperglycemia symptoms, such as polyuria, polydipsia, accidental weight loss or dehydration;
- •Habitual diarrhea, irritable bowel syndrome, clinically significant abnormal gastric emptying (such as gastric outlet obstruction), severe chronic gastrointestinal diseases (such as active ulcer within 6 months), long-term medication with direct impact on gastrointestinal peristalsis, or gastrointestinal surgery;
- •Have obvious blood system diseases (such as aplastic anemia, myelodysplastic syndrome), or any disease causing hemolysis or red blood cell instability (such as malaria), or accompanied by hemoglobin diseases (such as sickle type red blood cell disease) that may affect the determination of HbA1c level;
- •Obvious autonomic neuropathy, such as urinary retention, orthostatic hypotension, diabetic diarrhea or gastroparesis.
- •History of heart failure (NYHA class Ⅲ and Ⅳ, Appendix 2), or history of acute myocardial infarction or unstable angina within 6 months before screening, or history of coronary angioplasty, coronary stent implantation or coronary bypass surgery within 6 months before screening, or recent cardiac surgery plan;
- •Serious trauma, infection or operation that may affect blood glucose control occurred within one month before screening;
- •In the first two months of the screening, the drug with weight control effect was used or the operation that can lead to weight instability was performed, or the drug is currently in the weight-loss plan and is not in the maintenance stage;
- •Completed or withdrawn an intervention clinical trial within 3 months before screening, or is currently conducting the intervention clinical trial, or participated in other medical research activities, which is not suitable for the study according to the judgment of the researcher;
- •Those who frequently drink alcohol (more than 21 units (male) and 14 units / week (female) (1 unit = 360ml beer; or 150ml wine; or 45ml white wine) in the three months before screening, or who can't stop drinking during the test;
- •Those who are addicted to smoking (more than 10 cigarettes per day or the same amount of tobacco) within 3 months before screening or who cannot quit smoking (stop nicotine intake) during the trial;
- •Those who lost / donated more than 400 ml blood within 3 months before screening (except female physiological blood loss), received blood transfusion or used blood products, or planned to donate blood within 1 month (30 days) after the end of the trial or during the trial;
- •To screen the patients with unstable thyroid function (such as thiourea and thyroid hormone drugs) in the first 6 months, with poor control of hypothyroidism or history of hypothyroidism;
- •In the first 6 months of screening, there was a history of diabetic acute metabolic complications (diabetic ketoacidosis, hyperosmotic nonketotic coma, diabetic lactate acidosis);
- •In the screening period, when no pacemaker was installed, 12 lead ECG showed second degree or third degree atrioventricular block or qtcb interval prolonged more than 500 ms;
- •The results of clinical laboratory examination in screening period meet any of the following criteria:
- •Hemoglobin (Hgb) < lower limit of normal value (LLN);
- •Aspartate transaminase (AST) or alanine transaminase (ALT) > 2 times of upper limit of normal value (ULN);
- •Total bilirubin (TBIL) > 1.5 times the upper limit of normal value (except for known Gilbert syndrome which meets the following requirements, that is, part of bilirubin indicates that the combined bilirubin is less than 35% of total bilirubin);
- •Triglyceride (TG) ≥ 5.7mmol/l;
- •Estimated glomerular filtration rate < 60 ml / min (estimated by Cockroft Gault formula);
- •Fasting C peptide < 1.0 ng / ml (333 pmol / L);
- •Hepatitis B surface antigen, hepatitis C virus antibody, Treponema pallidum antibody or human immunodeficiency virus antibody were screened positive;
- •Poor blood pressure control (SBP ≥ 160mmhg and / or DBP ≥ 100mmhg);
- •Patients with history of needle syncope, blood syncope or intolerant of venipuncture;
- •Those with a history of drug abuse or positive drug abuse screening;
- •Patients with obvious mental disorders, epilepsy and other persons without behavioral or cognitive abilities;
- •Female subjects in pregnancy, lactation, or with pregnancy intention, or positive pregnancy test (hCG test); and female subjects of childbearing age who can not take effective contraceptive measures (effective contraceptive measures include abstinence, sterilization, intrauterine device, or diaphragm method stipulated by local laws) during the test period;
- •The subject may not complete the study for other reasons or the researcher thinks it should not be included.
研究组 & 干预措施
SY-008-6mg/d
2mg TID. The subjects were given the drug for the first time before breakfast in D1, and then continued to take the drug daily until dinner in D7, and left after PD sample collection and safety assessment before breakfast in D8. The researchers will decide whether to move on to the next stage，12mg/d.
干预措施: SY-008 (Drug)
SY-008-12mg/d
4mg TID. The subjects were given the drug for the first time before breakfast in D1, and then continued to take the drug daily until dinner in D7, and left after PD sample collection and safety assessment before breakfast in D8. The researchers will decide whether to move on to the next stage，18mg/d.
干预措施: SY-008 (Drug)
SY-008-18mg/d
6mg TID. The subjects were given the drug for the first time before breakfast in D1, and then continued to take the drug daily until dinner in D7, and left after PD sample collection and safety assessment before breakfast in D8, and then the test will be terminated.
干预措施: SY-008 (Drug)
SY-008 matching placebo
Oral administration of the same number of tablets in the corresponding test group.
干预措施: SY-008 matching placebo (Drug)
结局指标
主要结局
Maximum postprandial (breakfast, lunch, dinner) blood glucose added value.
时间窗: 7 days
Compared with placebo, the maximum change in glucose from baseline at D7.
Blood glucose AUC (AUC 0-4,AUC 4-10, AUC 10-14, AUC 0-24) in different periods.
时间窗: 7 days
Compared with placebo, the mean change in glucose AUC from baseline at D7.
The Safety and tolerance of SY-009，Collecting Number of subjects with adverse events as assessed by CTCAE V5.0.
时间窗: 7 days
Number of subjects with adverse events, major adverse events, serious adverse events, abnormal Laboratory Values, abnormal vital signs, Abnormal physical examination, Abnormal ECG data，Gastrointestinal adverse reactions (diarrhea, etc.) and hypoglycemia events.
C-peptide concentration changes before and after meal.
时间窗: 7 days
Compared with placebo, the mean change from baseline at D7.
The changes of insulin concentration before and after meal.
时间窗: 7 days
Compared with placebo, the mean change from baseline at D7.
GLP-1 concentration changes before and after meal.
时间窗: 7 days
Compared with placebo, the mean change from baseline at D7.
GIP concentration changes before and after meal.
时间窗: 7 days
Compared with placebo, the mean change from baseline at D7.
次要结局
- Peak time (Tmax)(1 day)
- Terminal elimination rate constant (λ z)(1 day)
- Steady state peak concentration (Cmax, SS).(7 days)
- Peak concentration (Cmax)(1 day)
- Terminal elimination half-life (T1 / 2)(1 day)
- Area under the drug time curve from 0 to the last detectable time (auc0-t)(1 day)
- Apparent distribution volume (VZ / F).(1 day)
- Area under the drug time curve (auc0 - ∞) from 0 to infinite time(1 day)
- Steady state terminal elimination half-life (T1 / 2, SS).(7 days)
- Auc0 - ∞ extrapolation percentage (% aucex)(7 days)
- Apparent clearance (CL / F)(1 day)
- Steady state peak time (Tmax, SS).(7 days)
- Area under drug time curve (auc0-t, SS) from steady state 0 to last detectable time.(7 days)
- The area under the drug time curve (auc0 - ∞, SS) of steady state from 0 to infinite time.(7 days)
- Accumulation ratio (rauc, rcmax)(7 days)
- Stable Valley concentration (ctrough, SS).(7 days)